Prenatal Antibiotics and Breast Milk / Neonatal IgA

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18-40
SponsorFondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

About this trial

In this biological study, the investigators will evaluate the levels of breast milk IgA, neonatal fecal IgA, and the composition of breast milk and fecal microbiota throughout the first 12 months of life in neonates born to mothers treated or not treated with prenatal antibiotics for at least 7 days after the 32nd weeks of gestation

Eligibility criteria

Qualifiers

expression of written informed consent

an antibiotic treatment (any molecule) for at least 7 days consecutively after the 32 weeks of pregnancy (or the absence of exposure to any systemic antibiotic treatment during pregnancy for the control group)

the intention to breastfeed their neonates as long as possible during the first year of life

Disqualifiers

absence of written informed consent

the intention to formula feed exclusively (or the presence of significant maternal concerns about breastfeeding)

a maternal antibiotic treatment shorter than 7 days

the presence of pre-existing maternal immune-mediated disorders (including immunodeficiencies and chronic infectious diseases)

Trial design

Treatments tested in this trial

  • Antibiotics

Treatment groups

82 Participants
are divided into 2 treatment groups

Sponsors and collaborators